Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors

Company Appointments - Avacta Therapeutics has appointed David Bryant and Richard Hughes as Non-Executive Directors, effective immediately [1] - David Bryant brings over 35 years of experience in the pharmaceutical industry, having held leadership roles at GSK and Pfizer, and was part of the management team at Clinigen Group during its IPO and subsequent sale for $1.6 billion [2] - Richard Hughes has over 30 years of corporate finance experience in UK capital markets, including roles in IPOs, equity capital raising, and M&A, and was a founder of Zeus Capital [3] Strategic Focus - The appointments are aimed at enhancing the Board's capabilities as Avacta transitions into a dedicated therapeutics company, focusing on its pre|CISION platform [4] - The pre|CISION platform is designed to deliver potent anti-tumor payloads directly to tumors while minimizing side effects, which is expected to improve patient outcomes [5][9] Executive Insights - David Bryant expressed enthusiasm about collaborating with the executive management team, particularly with the recent advancements in the pre|CISION platform and the upcoming clinical program [5] - Richard Hughes highlighted the potential impact of the pre|CISION platform on therapeutic standards and his commitment to leveraging his experience in fundraising and business scaling to benefit shareholders [5] Company Overview - Avacta Therapeutics is a clinical-stage life sciences company focused on developing peptide drug conjugates that utilize the pre|CISION platform to enhance cancer therapy effectiveness [8] - The pre|CISION platform utilizes a tumor-specific protease to release active drug payloads in the tumor microenvironment, thereby reducing systemic exposure and toxicity [9]